Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

RedHill's COVID-19 Candidate Reduces ARDS-Related Blood Clotting in Preclinical Study

americanpharmaceuticalreviewDecember 16, 2020

Tag: RedHill , COVID-19 , ARDS , opaganib , thrombosis

PharmaSources Customer Service